Jakarta, IO – Indonesia is one of the countries that has cases of dengue fever, formerly known as dengue hemorrhagic fever (DBD), due to the climate and demographic situation. Financing data from the 2020 Health Insurance Administration (BPJS) shows that the cost of treating dengue fever at first-level health facilities (FKTP) ranges from IDR 883 million to IDR 3.7 billion per month in 2020. Dengue fever has an impact on the quality of life, and can put stress on families, the health care system, and the economy.
“The interaction between agent, host, and environment in dengue fever causes everyone to be at risk of infection. However, the highest group of dengue fever sufferers is aged 0-14 years, namely 49.8%. Dengue fever cases are exacerbated by current climate change. For this reason, the national strategy in tackling dengue fever towards zero dengue deaths by 2030, includes eradicating mosquito nests through the 3Mplus Movement, namely draining, covering, recycling items that can be used as breeding grounds for the Aedes aegypti mosquito and G1R1J (One House One Jumantik Movement,” said dr. Asik Surya, MPPM, Coordinator of Arbovirosis Substances, Directorate of Infectious Disease Prevention and Control, Ministry of Health at “the 2023 InaHEA Biennial Scientific Meeting”, end of October 2023.
On this occasion, Prof. Dr. drg. Mardiati Nadjib, M.Sc, from Faculty of Public Health University of Indonesia in her presentation on the topic “The Economic Burden of Dengue: Understanding the Costs and Impacts”, said that Aedes aegypti and Aedes albopictus are the primary and secondary vectors for transmitting dengue fever. “The average annual number of cases reported to health authorities in Indonesia was more than 129,000 for the period between 2004 and 2010. The economic burden comes from the costs of inpatient (922,000 people) and outpatient care (1.7 million people), while self-care (4.6 million people) so they have to stop working or going to school. It is estimated that we loses 311,744 disability-adjusted life years (DALY’s) every year, consisting of 71.9% due to disability and 28.1% due to fatalities. If the number of cases increases, of course, this burden will increase, including the burden on BPJS Health and the Government and society itself,” she stated.
Read: New Case Of Monkeypox Recorded– Do Not Panic, Stay Alert
In a separate interview, Andreas Gutknecht, President Director of PT Takeda Innovative Medicines, said that Takeda appreciates InaHEA’s contribution in raising awareness about the burden of dengue fever in Indonesia and its impact on public health. “We are also honored by the trust given by the Ministry of Health in establishing a strong partnership for various prevention efforts, in line with the goal of zero deaths from dengue fever in Indonesia by 2030. Our commitment to this disease is reflected in our involvement in initiatives such as KOBAR (Joint Coalition Fight Dengue) as one of the founding members and in implementing the #Ayo3MPlusVaksinDBD community campaign which supports comprehensive dengue fever prevention and control efforts.” (est)